Head-to-head evidence
HRS-9821 vs TQC3721
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline
HRS-9821
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05622864 · Phase 1 · completed
The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet.
TQC3721
Developed by Sino Biopharmaceutical
NCT06527144 · Phase 2 · completed
The trial randomized 240 participants to two TQC3721 doses or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinically relevant lung-function measure FEV1, but the registry does not report whether the comparison met its prespecified endpoint.
Next expected readout: February 2027 · NCT07464587 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-9821's landscape · TQC3721's landscape